[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 24, 1997

Mesalamine-Induced Lung Disease

Author Affiliations

Madrid, Spain

Arch Intern Med. 1997;157(4):462. doi:10.1001/archinte.1997.00440250122018

Mesalamine (5-aminosalicylic acid), which is a component of sulfasalazine, has been used to treat inflammatory bowel diseases.1 Most adverse pulmonary symptoms caused by treatment with sulfasalazine have been attributed to sulfapyridine.2 Therefore, we thought it would be of interest to your readers to report a case involving an adverse pulmonary reaction to mesalamine therapy in a patient with ulcerative colitis.

Report of a Case.  A 60-year-old nonsmoking man was admitted to the hospital for increasing dyspnea, low fever, dry cough, and weight loss. All these symptoms developed 4 weeks after treatment with mesalamine was started for his first episode of ulcerative colitis. A chest x-ray film revealed bilateral interstitial infiltrates. The diffusion of carbon monoxide was 67% of the expected value. Physical examination identified rales in the lower fields. Investigations showed a white blood cell count of 7.9X109/L with 0.13 eosinophils. The erythrocyte sedimentation rate was 133 mm/h,

First Page Preview View Large
First page PDF preview
First page PDF preview